Revenue Growth - Subscription revenue increased to $891.7 million for the nine months ended September 30, 2025, compared to $804.2 million for the same period in 2024, reflecting a growth of approximately 10.5%[163] - Cloud Subscription Annual Recurring Revenue (ARR) increased to $968,623,000 in 2025 from $747,811,000 in 2024, representing a growth of 29.5%[186] - Total Annual Recurring Revenue reached $1,747,823,000 in 2025, up from $1,681,776,000 in 2024, marking an increase of 3.9%[186] - Total revenues increased to $439.2 million during the three months ended September 30, 2025, a 4% increase from $422.5 million in the same period of 2024[220] - Subscription revenues rose to $320.7 million (73% of total revenues) for the three months ended September 30, 2025, an 11% increase from $287.9 million (68% of total revenues) in 2024[222] - Cloud subscription revenues increased by 31% to $230.4 million (52% of total revenues) for the three months ended September 30, 2025, compared to $175.8 million (42% of total revenues) in 2024[228] - Total revenues for the nine months ended September 30, 2025, reached $1,250.4 million, a 3% increase from $1,211.7 million in the same period of 2024[221] Customer Retention and Migration - Cloud Subscription Net Revenue Retention (NRR) was 120% for the nine months ended September 30, 2025, compared to 126% for the same period in 2024[179] - The company signed agreements to migrate approximately 16.6% of its installed base maintenance and self-managed on-premises revenue to its cloud solution[173] - Cloud Subscription Net Retention Rate decreased to 120% in 2025 from 126% in 2024, indicating a decline in customer retention[186] - The company expects a continued decrease in Self-managed Subscription ARR and Maintenance ARR as it shifts focus from perpetual licenses to cloud offerings[192][194] - The company expects self-managed subscription support and maintenance revenues to continue to decrease gradually as migrations to cloud subscription offerings persist[233][236] Expenses and Cost Management - Adjusted EBITDA for the three months ended September 30, 2025, was $164,832,000, compared to $154,789,000 in 2024, reflecting a year-over-year increase of 6.7%[199] - Total operating expenses for the three months ended September 30, 2025, were $297.3 million, a slight increase from $289.9 million in 2024[216] - Research and development expenses are anticipated to decrease as a percentage of total revenues due to a focus on cloud subscription offerings[208] - Sales and marketing expenses are also expected to decline as a percentage of total revenues, aligning with the company's cloud-only strategy[209] - Research and development expenses increased to $85.4 million (19% of total revenues) for the three months ended September 30, 2025, compared to $80.3 million (19% of total revenues) for the same period in 2024, an increase of $5.1 million (6%)[249] - Sales and marketing expenses increased to $139.5 million (32% of total revenues) during the three months ended September 30, 2025, compared to $133.5 million (32% of total revenues) during the same period in 2024, an increase of $6.0 million (5%) due to higher personnel-related expenses[251] Profitability and Income - GAAP net income for the three months ended September 30, 2025, was $3,998,000, a significant improvement from a net loss of $13,985,000 in 2024[199] - Income from operations increased to $60.9 million for the three months ended September 30, 2025, compared to $50.9 million in 2024[216] - Net income for the three months ended September 30, 2025, was $4.0 million, a recovery from a net loss of $14.0 million in the same period of 2024[216] Merger and Acquisition - A merger agreement with Salesforce is expected to close in the fourth quarter of Salesforce's fiscal year 2026 or early in fiscal year 2027, subject to regulatory approvals[158] - The merger consideration includes $25.00 per share in cash for Class A and Class B-1 common stock, and $0.0000100115 per share for Class B-2 common stock[157] - A termination fee of $253 million will be payable by the company to Salesforce under certain circumstances if the merger agreement is terminated[159] - The company entered into a Merger Agreement with Salesforce on May 26, 2025, agreeing to conduct business in the ordinary course and requiring Salesforce's consent for certain actions[287] Cash Flow and Financial Position - Cash provided by operating activities was $327.5 million for the nine months ended September 30, 2025, compared to $263.0 million in 2024[273] - Net cash provided by investing activities was $200.6 million for the nine months ended September 30, 2025, primarily due to $460.4 million in maturities of investments[275] - Net cash used in financing activities was $118.2 million for the nine months ended September 30, 2025, primarily due to $101.4 million in repurchases of common stock[279] - As of September 30, 2025, the company had $1,472.1 million in available cash, cash equivalents, and short-term investments, up from $1,232.4 million at the end of 2024[266] - The company has a credit agreement with JPMorgan Chase Bank for $1.9 billion in term loans and $250.0 million in commitments under a Revolving Credit Facility[267] - As of September 30, 2025, the company had long-term debt outstanding with a carrying value of $1.8 billion, with a hypothetical change in interest rate of 0.25% potentially increasing or decreasing interest expense by approximately $4.5 million annually[292] Foreign Exchange and Hedging - The company has cash flow hedges for Indian Rupee expense exposure, with a hypothetical 10% increase in foreign currencies relative to the U.S. dollar potentially resulting in an approximate $18.1 million positive impact on operating income for the nine months ended September 30, 2025[294] - The notional amounts of foreign exchange forward contracts as of September 30, 2025, were to buy $95.3 million worth of Indian rupees[296] - The company has entered into float-to-float cross-currency swap contracts with an aggregate notional amount of €300 million to hedge a portion of its net investment in European operations[297] Compliance and Governance - The company was in compliance with all covenants of the Credit Agreement as of September 30, 2025[285] - The Credit Agreement stipulates that if the aggregate principal amount of certain loans exceeds $15 million, the total net first lien leverage ratio cannot exceed 6.25 to 1.00[283] - There were no material changes in contractual and lease obligations for the nine months ended September 30, 2025, compared to the previous annual report[286] - The company has not experienced material changes to its critical accounting policies and estimates compared to those described in its Annual Report on Form 10-K filed on February 25, 2025[290]

Exhibit 99.1 Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2025 Third Quarter Revenue Delivered at High End of Guidance Framingham, MA (November 6, 2025) – Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights: "We delivered third quarter results at or above the high end of ...

Revenue Performance - Revenue for the third quarter of 2025 increased by 36.6% to $1.421 billion, compared to $1.040 billion in the same quarter of 2024, driven by a $384 million increase in truck brokerage revenue due to the Coyote acquisition[86]. - Revenue increased by 48.2% to $4.3 billion in the first nine months of 2025, compared to $2.9 billion in the same period of 2024[95]. Cost and Expenses - Cost of transportation and services in the third quarter of 2025 was $1.137 billion, or 80.0% of revenue, up from $809 million, or 77.8% of revenue in the same quarter of 2024, primarily due to a full quarter of Coyote activity[87]. - Cost of transportation and services was $3.4 billion, or 79.8% of revenue, in the first nine months of 2025, up from $2.2 billion, or 76.6% of revenue, in 2024[96]. - Direct operating expenses decreased by 2.0% to $48 million in the third quarter of 2025, representing 3.4% of revenue, down from 4.7% in the same quarter of 2024, attributed to cost reduction initiatives[88]. - Direct operating expense decreased by $9 million, or 5.9%, to $143 million, representing 3.3% of revenue in 2025 compared to 5.3% in 2024[97]. - SG&A expenses increased by 39.6% to $208 million in the third quarter of 2025, representing 14.6% of revenue, compared to 14.3% in the same quarter of 2024, mainly due to a full quarter of Coyote activity[89]. - SG&A expenses increased by $184 million, or 41.1%, to $632 million, but as a percentage of revenue decreased to 14.8% from 15.5%[98]. - Depreciation and amortization expense rose to $26 million in the third quarter of 2025, compared to $21 million in the same quarter of 2024, reflecting an increase from Coyote activity[90]. - Depreciation and amortization expense rose to $88 million in 2025 from $54 million in 2024, largely due to the Coyote acquisition[99]. Financial Performance - The net loss for the third quarter of 2025 was $14 million, compared to a net loss of $243 million in the same quarter of 2024, indicating improved financial performance[85]. - Net cash provided by operating activities was $44 million in the first nine months of 2025, compared to a net cash used of $5 million in the same period of 2024[109]. - Net cash used in investing activities decreased significantly to $56 million in 2025 from $1.1 billion in 2024, primarily due to the Coyote acquisition in 2024[110]. Taxation - The effective income tax rate for the third quarter of 2025 was 9.2%, compared to (0.4)% for the same quarter in 2024, influenced by nondeductible expenses during a pre-tax loss[93]. - The effective income tax rate for the first nine months of 2025 was 16.0%, compared to 2.2% for the same period in 2024[102]. Acquisition and Integration - The company acquired Coyote for $1.038 billion in cash, with an additional $10 million for working capital adjustments, enhancing its truckload freight brokerage services[78]. - Transaction and integration costs decreased significantly to $5 million in the third quarter of 2025 from $30 million in the same quarter of 2024, with costs related to the Coyote acquisition included[91]. Assets and Liabilities - Total current assets decreased by 10.3% to $1.2 billion as of September 30, 2025, from $1.3 billion at the end of 2024[108]. - Total liabilities decreased by $181 million from December 31, 2024, to September 30, 2025, primarily due to a decrease in third-party transportation costs[108]. Service Positioning - The last mile service is positioned within 125 miles of the majority of the U.S. population, serving a customer base of omnichannel and e-commerce retailers[77].

FIGS Releases Third Quarter 2025 Financial Results Achieved Net Income Margin of 5.8% and Adjusted EBITDA Margin of 12.4% Increasing Full Year 2025 Outlook SANTA MONICA, Calif., November 6, 2025 — FIGS, Inc. (NYSE: FIGS) (the "Company"), the global leading healthcare apparel brand dedicated to improving the lives of healthcare professionals, today released its third quarter 2025 financial results and published a financial highlights presentation on its investor relations website at ir.wearfigs.com/financial ...

Investment Portfolio - As of September 30, 2025, the total fair value of investments was $945.964 million, a decrease from $1,076.840 million on December 31, 2024[240] - Senior secured loans comprised 90.66% of the total portfolio as of September 30, 2025, valued at $857.636 million[240] - The company held investments in 54 companies as of September 30, 2025, down from 57 companies at the end of 2024[239] - The fair value of preferred stock/units decreased to $37.386 million as of September 30, 2025, from $82.641 million at the end of 2024[240] - The ending investment portfolio as of September 30, 2025, was $945.964 million, down from $1,066.100 million as of September 30, 2024[243] - As of September 30, 2025, 64.35% of the debt investment portfolio was rated 2, indicating acceptable business prospects and compliance with covenants[244] - The investment portfolio's beginning value was $1,076.840 million as of September 30, 2025, compared to $1,067.009 million as of September 30, 2024[243] Financial Performance - For the three months ended September 30, 2025, the dollar-weighted annualized yield on debt investments was 16.83%, compared to 15.92% for the same period in 2024[241] - Total investment income for the three months ended September 30, 2025, was $36.7 million, unchanged from the same period in 2024, while for the nine months, it decreased to $107.3 million from $110.9 million[251][252] - Net investment income for the three months ended September 30, 2025, was $15.7 million, a slight decrease from $15.9 million in 2024, with per share figures of $0.43 and $0.41 respectively[260] - The net realized loss on investments for the three months ended September 30, 2025, was $1.3 million, attributed to losses on specific investments, while there were no realized gains or losses in the same period of 2024[262] - The net realized gain on investments for the nine months ended September 30, 2025, was $3.2 million, with gains from Gynesonics, Inc. offset by losses on other investments, while there were no realized gains or losses in 2024[263] - Total operating expenses for the nine months ended September 30, 2025, were $62.0 million, slightly up from $61.7 million in 2024, with per share expenses increasing to $1.67 from $1.57[255] Regulatory and Management - The company has elected to be treated as a regulated investment company (RIC) and a business development company (BDC) under relevant regulations[233] - The company is externally managed by Runway Growth Capital LLC, which provides investment advisory services[236] - The company is subject to various regulatory requirements, including the need to invest at least 70% of its assets in qualifying assets[233] Mergers and Acquisitions - The company is in the process of merging with SWK Holdings Corporation, with potential impacts on business operations and shareholder interests[234] - On October 9, 2025, the company entered into a Merger Agreement with SWK Holdings Corporation, involving multiple merger steps to consolidate operations[292] - The consummation of the Mergers is subject to customary closing conditions, including the effectiveness of the Registration Statement and approval by SWK's stockholders[299] - The Key Stockholder owns approximately 69.9% of the outstanding shares of SWK Common Stock and has agreed to vote in favor of the Merger Agreement[300] Liquidity and Debt - As of September 30, 2025, the company had $371.9 million in available liquidity, including $7.9 million in cash and cash equivalents, and $364.0 million available under its Credit Facility[273] - The company had a total of $1,162 thousand in forgone interest income from loans on non-accrual status as of September 30, 2025[246] - As of September 30, 2025, the company had $450.3 million in debt outstanding, with $25.0 million due within the next year[276] - The company completed $12.0 million of additional debt commitments from October 1, 2025, through November 6, 2025[291] Risk Factors - The company anticipates potential risks related to economic downturns, interest rate volatility, and competition for investment opportunities[229] - A hypothetical 200 basis point increase in interest rates could increase investment income by a maximum of $15.5 million, while a decrease could reduce it by a maximum of $8.8 million[304] - Investments denominated in foreign currencies are subject to risks associated with currency exchange rate fluctuations, which may be exacerbated by current economic conditions[308] Shareholder Returns - The company declared dividends of $13.0 million and $39.5 million for the three and nine months ended September 30, 2025, respectively, with the majority distributed in cash[286] - The company repurchased 1,213,391 shares for an aggregate purchase price of $12.5 million under the Fourth Repurchase Program as of September 30, 2025[284]

Product Development and Acquisitions - Pacira's long-acting, non-opioid analgesic EXPAREL is approved for managing postsurgical pain in patients aged six years and older, with a unique pMVL drug delivery technology[199]. - The acquisition of Flexion Therapeutics in November 2021 added ZILRETTA, which provides major relief for osteoarthritis knee pain for up to three months[199]. - In February 2025, Pacira acquired an 81% equity interest in GQ Bio Therapeutics, enhancing its gene therapy capabilities with the novel HCAd platform[199]. - An exclusive license agreement with AmacaThera for AMT-143 includes a $5 million upfront payment and potential future milestone payments, aligning with Pacira's growth strategy[208]. - The company has prioritized three other preclinical HCAd-based gene therapy programs, including PCRX-1002 for Dry Eye Disease and PCRX-1003 for Degenerative Disc Disease[241]. Clinical Trials and Research - The company expects to report results from an interim analysis of the Phase 2 ASCEND study for PCRX-201 by the end of 2026[208]. - New data from a Phase 1 trial of PCRX-201 showed sustained efficacy for up to three years, with improvements in pain and function across all severity subgroups[209]. - The company is advancing a Phase 2 clinical study known as ASCEND for PCRX-201 in knee osteoarthritis (OA), involving approximately 135 patients aged 45 to 80[237]. - The primary endpoint of the ASCEND study includes the number and percentage of treatment-emergent adverse events from Week 1 through Week 52[239]. - A Phase 3 study is underway to evaluate ZILRETTA for managing OA pain of the shoulder, potentially expanding its label[219]. - Clinical data indicates that EXPAREL significantly reduces opioid usage while improving postsurgical pain management[215]. - The iovera° system is a non-opioid device providing pain relief for knee OA, with clinical data showing significant reductions in opioid use post-surgery[221][223]. - PCRX-201, targeting the IL-1 pathway, showed promising results in a Phase 1 study with over 70% of patients experiencing a 50% or greater improvement in pain[236]. Financial Performance - Net product sales for the three months ended September 30, 2025, were $178.0 million, a 6% increase from $167.7 million in 2024[244]. - Total revenues for the nine months ended September 30, 2025, were $529.5 million, a 3% increase from $513.7 million in 2024[244]. - EXPAREL revenue increased by 6% and 5% for the three and nine months ended September 30, 2025, respectively, driven by a 9% and 6% increase in gross vial volume[244]. - ZILRETTA revenue increased by 2% in the three months ended September 30, 2025, but decreased by 2% in the nine months due to a 4% decrease in kit volume[245]. - The cost of goods sold decreased by 12% to $34.3 million for the three months ended September 30, 2025, contributing to a gross margin increase to 81%[250]. - Total research and development (R&D) expenses increased by 36% to $25.966 million for the three months ended September 30, 2025, and by 38% to $79.859 million for the nine months ended September 30, 2025, compared to the same periods in 2024[254]. - Sales and marketing expenses grew by 35% to $58.471 million for the three months and by 36% to $165.006 million for the nine months ended September 30, 2025, reflecting investments in customer awareness and education programs[263]. - Total selling, general and administrative expenses increased by 23% to $91.797 million for the three months and by 25% to $267.151 million for the nine months ended September 30, 2025[262]. Legal and Regulatory Environment - The ongoing U.S. government shutdown may impact the FDA's ability to review regulatory submissions, potentially affecting Pacira's operations[206]. - The company expects to incur additional legal costs related to defending its intellectual property against two Chinese generic drug manufacturers seeking to produce a generic version of EXPAREL[266]. Workforce and Operational Changes - The company implemented a reduction in force affecting 71 employees, approximately 8% of the total workforce, resulting in $3.7 million in employee termination benefit charges[211]. - The workforce reduction is expected to lead to an annual reduction in operating expenses of approximately $13.0 million, excluding one-time expenses[212]. - In the nine months ended September 30, 2025, the company recognized $3.7 million in pre-tax employee termination benefit charges due to a reduction in force at its Science Center Campus[275]. Economic and Market Conditions - Global economic conditions, including inflation and tariffs, may negatively impact Pacira's business and financial results[201]. - The U.S. and E.U. agreed to a trade deal in July 2025, setting a 15% tariff on most imports from the E.U., which could affect costs for Pacira[202]. Debt and Financing - The company entered into a $300.0 million senior secured revolving credit facility on July 3, 2025, to refinance existing debt and provide working capital[298]. - The company entered into a TLA Credit Agreement on March 31, 2023, securing a term loan of $150.0 million, which is scheduled to mature on March 31, 2028[303]. - The TLA Term Loan requires quarterly principal repayments starting at $2.8 million, increasing to $3.8 million by March 31, 2025, with a balloon payment of approximately $85.3 million due at maturity[304]. - The company completed a private placement of $287.5 million in 2.125% convertible senior notes due 2029, with all principal outstanding as of September 30, 2025[306]. - The company repurchased $200.0 million of its 0.750% convertible senior notes due 2025 for $191.4 million, resulting in a $7.5 million gain on early extinguishment of debt[307]. - The company anticipates that existing cash and cash equivalents will be sufficient to fund operating expenses and capital requirements for the next 12 months[310]. - The company may require additional debt or equity financing to meet future operating and capital requirements, with no committed external sources of funds[311].

Exhibit 99.1 FOR IMMEDIATE RELEASE CONTACT: (Investor Relations) (Corporate Press) Nicole Shevins Alan Lewis Senior Vice President Investor Relations & Corporate Communications Take-Two Interactive Software, Inc. Take-Two Interactive Software, Inc. (646) 536-3005 (646) 536-2983 Nicole.Shevins@take2games.com Alan.Lewis@take2games.com Head of Global Corporate Communications Take-Two Interactive Software, Inc. Reports Results for Fiscal Second Quarter 2026 Company raises fiscal year 2026 outlook Fiscal second ...

Exhibit 99.1 The Trade Desk Reports Third Quarter 2025 Financial Results The Trade Desk also announced an additional $500 million share repurchase authorization. LOS ANGELES--(BUSINESS WIRE)--November 6, 2025--The Trade Desk, Inc. ("The Trade Desk," the "Company" or "we") (NASDAQ: TTD), a provider of a global technology platform for buyers of advertising, today announced financial results for its third quarter ended September 30, 2025. "Q3 was another strong quarter for The Trade Desk, with revenue growing ...

Financial Performance - Net income for Q3 2025 was $9.9 million, or $0.18 per diluted share, down from $23.0 million, or $0.50 per diluted share, in Q3 2024[177] - Adjusted net income for Q3 2025 was $28.4 million, compared to $24.0 million in Q3 2024[177] - Noninterest income for the third quarter of 2025 increased by $2.2 million, or 20.3%, compared to the second quarter of 2025, driven by growth in wealth management and other income sources[209] - The company reported net income of $51.5 million in the first nine months of 2025, partially offset by $8.6 million in dividends paid[266] Acquisition of Bancorp Financial - The acquisition of Bancorp Financial was completed on July 1, 2025, with a total consideration of $189.4 million, including 7.9 million shares of Old Second common stock and $48.9 million in cash[173] - Bancorp Financial had approximately $1.43 billion in total assets, $1.19 billion in total loans, and $1.23 billion in total deposits at the time of acquisition[173] - The systems conversion for Bancorp Financial was successfully completed in October 2025[173] - The company realized a death benefit of $430,000 on BOLI in the third quarter of 2025, contributing to the increase in noninterest income[210] - The company experienced net cash inflows of $10.5 million from the acquisition of Bancorp Financial in July 2025[276] Income and Expenses - Noninterest expense increased by $23.9 million in Q3 2025, largely due to acquisition-related costs and adjustments[177] - Noninterest expense for Q3 2025 increased by $19.7 million, or 45.5%, compared to Q2 2025, and by $23.9 million, or 60.7%, compared to Q3 2024[215] - The increase in Q3 2025 noninterest expense was driven by $11.5 million in acquisition costs related to Bancorp Financial, accounting for 59.8% of the quarterly increase[215] - Salaries and employee benefits rose by $12.8 million in Q3 2025, with $8.4 million attributed to change in control, retention, and severance payouts from the Bancorp Financial acquisition[215] Loans and Credit Quality - Total loans increased by $1.28 billion as of September 30, 2025, compared to December 31, 2024, driven by $1.19 billion from the Bancorp Financial acquisition and $72.3 million in organic growth[182] - Nonperforming loans increased by $17.7 million to $48.0 million at September 30, 2025, from $30.3 million at December 31, 2024, but decreased by $4.3 million from $52.3 million at September 30, 2024[236] - The allowance for credit losses increased to $75.0 million as of September 30, 2025, compared to $43.6 million at December 31, 2024[239] - The provision for credit losses on loans was $19.7 million in the third quarter of 2025, primarily due to the inclusion of the powersport loan portfolio and related charge-offs[248] Capital and Ratios - All capital ratios were above regulatory requirements as of September 30, 2025, indicating a strong capital position[176] - The common equity tier 1 capital ratio was 12.44% as of September 30, 2025, exceeding the minimum requirement of 7.00%[267] - The tangible common equity to tangible assets ratio improved to 10.41% at September 30, 2025, compared to 10.04% at December 31, 2024[270] Deposits and Liquidity - Total deposits reached $5.76 billion as of September 30, 2025, reflecting a $991.5 million increase from $4.77 billion at December 31, 2024, and a $1.29 billion increase from $4.47 billion at September 30, 2024[260] - The average rate paid on total deposits increased by 19 basis points due to the higher cost profile of deposits acquired from Bancorp Financial[262] - As of September 30, 2025, the company's cash on hand liquidity totaled $116.5 million, an increase of $17.2 million compared to December 31, 2024[273] Interest Income and Margin - Net interest and dividend income increased to $82.8 million in Q3 2025 from $60.6 million in Q3 2024, primarily due to the acquisition of Bancorp Financial and organic loan growth[179] - The net interest margin increased to 5.03% in Q3 2025, up 41 basis points from 4.62% in Q3 2024, driven by the Bancorp Financial acquisition and higher security yields[193] - Net interest income (GAAP) for the nine months ended September 30, 2025, was $209,913 million, up from $180,051 million in 2024, representing a year-over-year increase of 16.6%[205] Market Conditions - The Federal Reserve Board reduced the Federal Funds target rate by 50 basis points in 2025 to a range of 3.75% - 4.00%[281] - The annual U.S. inflation rate for September 2025 rose to 3.0%, up from 2.7% in the previous quarter[287]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q _________________________________________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe ...